Cargando…
Use of lacosamide in children: experience of a tertiary medical care center in Brazil
Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Revinter Publicações Ltda.
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797266/ https://www.ncbi.nlm.nih.gov/pubmed/36577407 http://dx.doi.org/10.1055/s-0042-1758366 |
_version_ | 1784860655511142400 |
---|---|
author | Romão, Tayla Taynan Angelim, Abraão Iuri Medeiros Prado, Henrique Jannuzzelli Pires do Goes, Fernanda Veiga de Pires, Maria Elisa Paiva Fontana, Rosiane da Silva Pires, Lais de Carvalho Fernandes, Alexandre Ribeiro D'Andrea-Meira, Isabella |
author_facet | Romão, Tayla Taynan Angelim, Abraão Iuri Medeiros Prado, Henrique Jannuzzelli Pires do Goes, Fernanda Veiga de Pires, Maria Elisa Paiva Fontana, Rosiane da Silva Pires, Lais de Carvalho Fernandes, Alexandre Ribeiro D'Andrea-Meira, Isabella |
author_sort | Romão, Tayla Taynan |
collection | PubMed |
description | Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures. |
format | Online Article Text |
id | pubmed-9797266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Thieme Revinter Publicações Ltda. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97972662023-01-09 Use of lacosamide in children: experience of a tertiary medical care center in Brazil Romão, Tayla Taynan Angelim, Abraão Iuri Medeiros Prado, Henrique Jannuzzelli Pires do Goes, Fernanda Veiga de Pires, Maria Elisa Paiva Fontana, Rosiane da Silva Pires, Lais de Carvalho Fernandes, Alexandre Ribeiro D'Andrea-Meira, Isabella Arq Neuropsiquiatr Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures. Thieme Revinter Publicações Ltda. 2022-12-28 /pmc/articles/PMC9797266/ /pubmed/36577407 http://dx.doi.org/10.1055/s-0042-1758366 Text en Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Romão, Tayla Taynan Angelim, Abraão Iuri Medeiros Prado, Henrique Jannuzzelli Pires do Goes, Fernanda Veiga de Pires, Maria Elisa Paiva Fontana, Rosiane da Silva Pires, Lais de Carvalho Fernandes, Alexandre Ribeiro D'Andrea-Meira, Isabella Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
title | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
title_full | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
title_fullStr | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
title_full_unstemmed | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
title_short | Use of lacosamide in children: experience of a tertiary medical care center in Brazil |
title_sort | use of lacosamide in children: experience of a tertiary medical care center in brazil |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797266/ https://www.ncbi.nlm.nih.gov/pubmed/36577407 http://dx.doi.org/10.1055/s-0042-1758366 |
work_keys_str_mv | AT romaotaylataynan useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT angelimabraaoiurimedeiros useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT pradohenriquejannuzzellipiresdo useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT goesfernandaveigade useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT piresmariaelisapaiva useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT fontanarosianedasilva useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT pireslaisdecarvalho useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT fernandesalexandreribeiro useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil AT dandreameiraisabella useoflacosamideinchildrenexperienceofatertiarymedicalcarecenterinbrazil |